Management of Hypertension, Obesity, Lipids, and Diabetes with Glucagon-like Peptide 1 Receptor Agonists

Abstract

Abstract Hyperglycemia is considered one of the main risk factors for the development of cardiovascular diseases, and the situation becomes worse if the condition is associated with uncontrolled hypertension, dyslipidemia, and overweight or obesity. Since the first glucagon-like peptide 1 receptor agonist (GLP-1RA) being approved in 2005 for type 2 diabetes, the class has successfully developed newer compounds with more pronounced effects on glycemic control and body weight; not to forget the oral peptide in a pill as well; oral semaglutide. To manage hypertension, obesity, lipids, and diabetes, it is ascertained that a holistic approach is required or the class with pleiotropic benefits to treat accompanying metabolic disturbances. Over the years, the place for GLP-1RA therapy has changed with most guidelines recommending GLP-1RA therapy in patients with established or high risk of cardiovascular disease independently of glycemia.